An observational study in Long Covid, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by University of California, San Francisco · Observational
Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 20th largest by planned enrollment of the 37 observational ones that give a count, is one of 12 that started in 2026, is one of 37 observational ones, reaches primary completion later than 83 of the 83 other live ones, and was the 192nd registered.
604 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →63 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Stephanie B. Seminara, MD · Sites in United States
Ages 18–60
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 146 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (36%) stop at 75 or younger; 15 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 53 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 52 across the 155 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 194 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,170 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
University of California, San Francisco has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
29 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 29 to your calendar (.ics) → With an account.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to better understand the biological changes associated with Long COVID and to identify laboratory tests (biomarkers) that may help diagnose the condition and measure how it changes over time. Researchers will enroll people with Long COVID as well as people who have fully recovered after COVID-19 infection.
Participants will provide health information and biological samples, such as blood, saliva, stool, and, for some participants, tissue biopsies. These samples will be used to study the biological processes involved in Long COVID and to support the development of new diagnostic tests that may improve future research, clinical trials, and patient care.
The lack of a biomarker for Long COVID (LC) is the single biggest obstacle to the development of a cure for this disabling infection-associated chronic condition (IACC). Development of biomarkers to date has been sluggish and uncoordinated, in part due to the lack of resources invested in this effort and in part due to the lack of a central biospecimen collection, distribution, and analytic resource to support the work of laboratories who are developing compelling assays for this condition using novel technologies. Currently, the work of assay development is highly siloed - individual laboratories working with relatively small numbers of samples from participants from individual cohorts with a variable degree of clinical phenotyping are developing individual assays that have not been robustly validated or compared head-to-head with similar assays. The result has been a lack of progress in advancing Long COVID diagnostics, which in turn has limited the development of Long COVID treatments and ultimately a cure.
The UCSF Viral Immunology and Persistence Repeat Donor Cohort (VIPER) program aims to address these challenges by serving as a central, gold-standard resource to support the development of biomarkers for Long COVID. Developed within the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC) research program (UCSF IRB # 20-30479) - one of the most highly visible and productive Long COVID studies in the world - VIPER will enroll and deeply phenotype individuals with well-defined Long COVID as well as those who have fully recovered from SARS-CoV-2 infection. All participants will undergo a combination of non-invasive (blood, saliva, stool) and invasive (tissue biopsy) sampling using established procedures, with collection of ample amounts of biological specimens to support downstream biomarker development. VIPER specimens will be centrally housed and distributed to collaborating laboratories, who while blinded to the characteristics of the participants will generate measurements that are shared with a central data core for analysis. This will enable the determination of how each assay performs relative to both clinical and laboratory "gold standards" and how each assay performs relative to each other.
Following the identification and validation of these biomarkers, this program will also determine how these tests can be used to assess eligibility and outcomes in LC trials. Ultimately, the goal of VIPER is to promote the development of biomarker tests that can be utilized in the clinic setting to identify those who are likely to benefit from therapeutics targeting each of the mechanisms of Long COVID.
The study population will include adults with well-characterized Long COVID and adults who have recovered following SARS-CoV-2 infection. Participants will be enrolled from the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC) research program and through community outreach and referral efforts. The study aims to include individuals with a range of Long COVID symptom patterns and durations to support research on the biological mechanisms of the condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of a SARS-CoV-2 infection resulting in Long COVID symptoms, confirmed by the investigator, or
Exposure to SARS-CoV-2 without establishment of Long COVID.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
People experiencing Long COVID symptoms
People who have fully recovered from their COVID infection(s)
Participant age
The median age of study participants at enrollment
Time frame: Baseline visit
Participant sex
The proportion of men and women participating in the baseline visit.
Time frame: Baseline visit
Participant race/ethnicity
The proportion of participants from each demographic group
Time frame: Baseline visit
Proportion of participants previously hospitalized
The proportion of participants who were previously hospitalized
Time frame: Baseline visit
Colonoscopy Completed
The proportion of participants completing a research colonoscopy for the study
Time frame: Baseline visit
Protocol complete
The proportion of enrolled participants who complete all study activities
Time frame: Up to 6 weeks from baseline
Long COVID Symptom Assessment
Participant-reported assessment for presence and severity of persistent post-COVID-19 symptoms
Time frame: Screening, baseline, and up to 6 weeks
Qualify of Life Assessment (Global Health Score)
Measure of overall health-related quality of life
Time frame: Screening, baseline, and up to 6 weeks
Mental Health Symptom Assessment
An instrument such as the PHQ-9 will be used to assess participants' overall mental health status. These will include questions about anxiety and depression, independent of Long COVID association.
Time frame: Screening visit
Cognitive Symptom Assessment
An instrument such as the Everyday Cognition survey will be used to asses perceived changes in everyday cognitive function across domains compared to participants' pre-COVID baselines.
Time frame: Screening visit
Fatigue Symptom Assessment
An instrument such as the FACIT-Fatigue will be used to assess fatigue severity and its impact on daily activities.
Time frame: Baseline and up to 6 weeks
Gastrointestinal Symptom Assessment
An instrument such as the Modified Gastrointestinal Symptom Rating Scale (GSRS) will be used to assess the severity of gastrointestinal symptoms across multiple symptom domains.
Time frame: Baseline and up to 6 weeks
Neurocognitive Function Assessment
A computer-based neurocognitive test such as CNS Vital Signs will be used to assess cognitive function across multiple domains including memory, attention, psychomotor speed, and executive function.
Time frame: Baseline and up to 6 weeks
Physical Function Symptom Assessment
An instrument such as the PROMIS Physical Function will be used to assess participants' ability to perform physical activities of daily living.
Time frame: Baseline and up to 6 weeks
Autonomic Symptom Assessment
A questionnaire such as the COMPASS-31 or Orthostatic Hypotension Questionnaire (OHQ) will be used to assess autonomic nervous system symptoms across symptom domains.
Time frame: Baseline and up to 6 weeks
Post-Exertional Malaise Symptom Assessment
An instrument such as the DSQ-PEM will be used to assess the severity of post-exertional malaise
Time frame: Baseline and up to 6 weeks
Grip Strength Test
Objective measure of hand grip strength using a hand dynamometer
Time frame: Up to 6 weeks from baseline
30-Second Sit-to-Stand Test
Objective performance test measuring the number of full stands from a seated position completed in 30 seconds
Time frame: Up to 6 weeks from baseline
Active Standing Test
Objective measurement of changes in heart rate and blood pressure upon transition from lying/sitting to standing
Time frame: Up to 6 weeks from baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.
Of 98 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 59 months is above that.
Counting every sponsor, half of 105 studies reached it within 27 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
University of California, San Francisco →